GenrAb – a developer of first-in-class neuroprotective therapies – announced completion of a private placement with aggregate gross proceeds of $5.6 million. And GenrAb is optimizing the world’s most effective biological therapy creation engine, which is the human adaptive immune system. Utilizing proprietary immunogenetic models to search the cerebrospinal fluid (CSF) of patients undergoing active neurological disease, GenrAb identified novel, neuronally-specific and neuroprotective antibodies.
This is evident from GenrAb’s lead antibody therapy, TGM-010, which has repeatedly and independently demonstrated the capability to cross the blood-brain barrier (BBB), internalize specifically into neurons, and engage key stress management machinery to reduce disability.
This funding enables GenrAb to aggressively advance TGM-010 through IND and towards human clinical studies in 2026.
GenrAb is an emerging leader in North Texas’s life sciences ecosystem, winning multiple awards for its unique approach to treating neurodegeneration. And the company was created using technology exclusively licensed from the UT Southwestern Medical Center and is headquartered in BioLabs at Pegasus Park, Dallas.
KEY QUOTES:
“We believe GenrAb has an unprecedented opportunity to develop a novel class of antibody therapeutics that protect neurons under stress. TGM-010 continues to validate our unique approach that unlocks naturally occurring human antibodies involved in reducing neurodegeneration and maintaining neuronal health. This financing is a key milestone in bringing our first-in-class neuroprotective antibody therapies to the clinic. We’re honored that our investment partners enthusiastically share our vision to seismically disrupt the worldwide neurological treatment market that remains significantly underserved given the number of neurodegenerative diseases for which no effective treatments are available.”
GenrAb’s Chief Executive Officer, Larry Tiffany
“Actium is pleased to have led this capital raise during a period of extreme market volatility. The strong demand for investment in GenrAb, after deep diligence by our team and others, resulted in a sophisticated and diverse syndicate including Salem Partners, GPG Ventures, Research Bridge Partners and Maytal Capital. This financing is a vote of confidence in the novel biology driving GenrAb’s innovative and disruptive technology, which has the potential to transform the treatment of CNS disorders to the great benefit of society.”
Jun Il Kwun, Managing Director of the Actium Group
What the funding will be used for: The proceeds from this seed financing will be used to accelerate the development of its lead candidate TGM-010, a novel, fully-human, neuroprotective antibody which is the first in a growing pipeline of novel neurotherapeutic antibodies selected for their potential to become high impact medicines.
